Want to know if this job is worth applying to?
Deutschland
Remote only
OVERVIEW
We are currently seeking a Freelance Site Contract Manager* to support our Clinical Outsourcing and Contract Management team on a temporary basis. This freelance engagement is based on business demand, with project-based work packages assigned as needed and varying in scope and volume. In this role, you will work in an interdisciplinary environment with employees across Germany and the US, contributing to our mission of delivering novel PRAME immunotherapies to patients with cancer.
YOUR MISSION
Your primary responsibility will be to independently manage Clinical Trial Agreements (CTAs) and site budgets for clinical trial sites in Germany and Spain, ensuring timely contract execution in collaboration with Clinical Operations, Legal, and other stakeholders. Key responsibilities include:
YOUR PROFILE
You bring experience in clinical trial site contracting within the pharmaceutical, biotechnology, or CRO industry and have a proven track record of independently negotiating and executing CTAs and site budgets in Germany and Spain, strong knowledge of relevant clinical trial regulations and country-specific requirements, and excellent communication skills in German and English.
Experience in oncology, cell therapy, study start-up activities, sponsorship and CRO environments, as well as additional language skills and broader European contracting expertise, are considered an advantage.
NOTICE
*We value diversity and inclusion. Immatics N.V. and all Immatics subsidiaries are equal opportunity employers that evaluate qualified applicants without regard to race, color, national origin, religion, sex, age, marital status, disability, veteran status, sexual orientation, gender identity, or other characteristics protected by law.
ABOUT IMMATICS
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.